Compounds > dalteparin
Page last updated: 2024-10-18

dalteparin and Left Ventricular Dysfunction

dalteparin has been researched along with Left Ventricular Dysfunction in 7 studies

Dalteparin: A low-molecular-weight fragment of heparin, prepared by nitrous acid depolymerization of porcine mucosal heparin. The mean molecular weight is 4000-6000 daltons. It is used therapeutically as an antithrombotic agent. (From Merck Index, 11th ed)

Research

Studies (7)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's1 (14.29)18.2507
2000's4 (57.14)29.6817
2010's0 (0.00)24.3611
2020's2 (28.57)2.80

Authors

AuthorsStudies
Elikowski, W1
Psuja, P1
Lewandowski, K1
Przybył, M1
Wendland, M1
Wróblewski, D1
Jazienicki, B1
Przybył, L1
Zawilska, K1
Sudhakar, D1
Kamran, H1
Chen, N1
Mims, M1
Hamzeh, I1
Chen, PF1
Yi, JL1
Pei, JY1
Tang, L1
Fang, ZF1
Zhou, SH1
Hu, XQ1
Meurin, P1
Renaud, N1
Weber, H1
Tabet, JY1
Grosdemouge, A1
Bourmayan, C1
Ben Driss, A1
Ellis, SG1
Armstrong, P1
Betriu, A1
Brodie, B1
Herrmann, H1
Montalescot, G1
Neumann, FJ1
Smith, JJ1
Topol, E1
Kukla, P1
Bryniarski, L1
Korpak-Wysocka, R1
Bartuś, S1
Giszterowicz, D1
Dobrowolski, W1
Dudek, D1
Agati, L1
Funaro, S1
Madonna, M1
Sardella, G1
Garramone, B1
Galiuto, L1

Clinical Trials (1)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
A Muticenter, Randomized, Double-blind, Placebo Controlled Trial Comparing the Efficacy and Safety of Reteplease and Abciximab Combination Therapy With Abciximab Alone Administered Early or Just Prior to Primary Primary Percutaneous Coronary Intervention [NCT00046228]Phase 32,461 participants (Actual)Interventional2002-08-31Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

All-Cause Mortality Through 1 Year

All-cause mortality through 1 year from randomization. (NCT00046228)
Timeframe: 1 year

Interventionparticipants (Number)
Primary PCI Group56
Abciximab Facilitated PCI Group60
Reteplase/Abciximab Facilitated PCI Group52

All-Cause Mortality Through 90 Days

All cause mortality occurred through 90 days from randomization. (NCT00046228)
Timeframe: 90 days

Interventionparticipants (Number)
Primary PCI Group36
Abciximab Facilitated PCI Group45
Reteplase/Abciximab Facilitated PCI Group43

Complications of MI as Defined in the Primary Outcome Measure Through 90 Days

The complications of myocardial infarction (MI) is defined as any event of rehospitalization or emergency department visit for CHF, cardiogenic shock, or resuscitated ventricular fibrillation occurring > 48 hours after randomization. (NCT00046228)
Timeframe: 90 Days

Interventionparticipants (Number)
Primary PCI Group72
Abciximab Facilitated PCI Group61
Reteplase/Abciximab Facilitated PCI Group61

Subjects With Any Investigator Reported Bleeding Events Through Discharge/Day 7

(NCT00046228)
Timeframe: Discharge/Day 7

Interventionparticipants (Number)
Primary PCI Group139
Abciximab Facilitated PCI Group178
Reteplase/Abciximab Facilitated PCI Group271

Subjects With Intracranial Hemorrhage (Including Hemorrhagic Transformation) Through Discharge/Day 7

All cases of cerebrovascular event were confirmed by a CEC (Clinical Endpoints Committee). (NCT00046228)
Timeframe: Discharge/Day 7

Interventionparticipants (Number)
Primary PCI Group1
Abciximab Facilitated PCI Group0
Reteplase/Abciximab Facilitated PCI Group5

Subjects With Non Intracranial Thrombolysis In Myocardial Infarction (TIMI) Bleeding Events Through Discharge/Day 7

Subjects with nonintracranial TIMI bleeding (either major or minor) through discharge/day 7, originating from vascular instrumentation sites, non-instrument related bleeding, as well as overall, were examined. (NCT00046228)
Timeframe: Discharge/Day 7

Interventionparticipant (Number)
Primary PCI Group55
Abciximab Facilitated PCI Group81
Reteplase/Abciximab Facilitated PCI Group118

Subjects With Pre-Specified Complications of Index Myocardial Infarction Through Discharge/Day 7

Number of subjects with one or more of the following: 2nd or 3rd Degree AVB, Asystole, Sustained V Tach, A Fib/Flutter, EMD/Pulseless Electrical Activity, Heart Failure, Tamponade, Myocardial Rupture, Papillary Muscle Rupture, Ventricular Septal Defect, Pulmonary Embolism, Systemic Arterial Embolism and/or Pericarditis/Pericardial Effusion. (NCT00046228)
Timeframe: Discharge/Day 7

Interventionparticipants (Number)
Primary PCI Group128
Abciximab Facilitated PCI Group122
Reteplase/Abciximab Facilitated PCI Group120

Subjects With Severe Thrombocytopenia Through Discharge/Day 7

Severe thrombocytopenia is defined as platelet count < 50,000 cells/μL. (NCT00046228)
Timeframe: Discharge/Day 7

Interventionparticipants (Number)
Primary PCI Group11
Abciximab Facilitated PCI Group16
Reteplase/Abciximab Facilitated PCI Group16

Subjects With ST-Segment Resolution > 70% From Baseline at 60 to 90 Minutes Following Randomization

(NCT00046228)
Timeframe: 60 to 90 minutes

Interventionparticipants (Number)
Primary PCI Group75
Abciximab Facilitated PCI Group85
Reteplase/Abciximab Facilitated PCI Group108

The Composite of All-Cause Mortality or Complications of MI at 90 Days.

Occurs within 90 days and is composite of all-cause mortality or complications of myocardial infarction (MI) (rehospitalization or emergency department visit for congestive heart failure (CHF), cardiogenic shock, or resuscitated ventricular fibrillation occurring > 48 hours after randomization). (NCT00046228)
Timeframe: 90 days

Interventionparticipants (Number)
Primary PCI Group86
Abciximab Facilitated PCI Group86
Reteplase/Abciximab Facilitated PCI Group81

Trials

4 trials available for dalteparin and Left Ventricular Dysfunction

ArticleYear
[Low molecular weight heparin (Fraxiparine) as adjunctive therapy with thrombolysis for acute myocardial infarction: a pilot study with a one year follow up].
    Polskie Archiwum Medycyny Wewnetrznej, 1996, Volume: 95, Issue:1

    Topics: Adult; Aged; Aspirin; Echocardiography; Female; Fibrinolytic Agents; Follow-Up Studies; Humans; Male

1996
[Treatment of left intraventricular thrombosis with low molecular weight heparin].
    Archives des maladies du coeur et des vaisseaux, 2003, Volume: 96, Issue:4

    Topics: Aged; Anticoagulants; Echocardiography; Enoxaparin; Feasibility Studies; Female; Heparin, Low-Molecu

2003
Facilitated percutaneous coronary intervention versus primary percutaneous coronary intervention: design and rationale of the Facilitated Intervention with Enhanced Reperfusion Speed to Stop Events (FINESSE) trial.
    American heart journal, 2004, Volume: 147, Issue:4

    Topics: Abciximab; Aged; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Anticoagulants; Combined Mo

2004
Does coronary angioplasty after timely thrombolysis improve microvascular perfusion and left ventricular function after acute myocardial infarction?
    American heart journal, 2007, Volume: 154, Issue:1

    Topics: Angioplasty, Balloon; Cineangiography; Enoxaparin; Female; Fibrinolytic Agents; Humans; Male; Middle

2007

Other Studies

3 other studies available for dalteparin and Left Ventricular Dysfunction

ArticleYear
A Sticky Situation: Aortic Valve Thrombus in Patient with Antiphospholipid Antibody Syndrome and Immune Thrombocytopenia.
    The American journal of medicine, 2020, Volume: 133, Issue:8

    Topics: Adult; Anticoagulants; Antiphospholipid Syndrome; Aortic Valve; Aortic Valve Stenosis; Benzoates; Bi

2020
Post-Procedural Anticoagulation After Primary Percutaneous Coronary Intervention for Anterior Acute Myocardial Infarction With Severe Left Ventricular Dysfunction.
    Circulation journal : official journal of the Japanese Circulation Society, 2020, 09-25, Volume: 84, Issue:10

    Topics: Aged; Anterior Wall Myocardial Infarction; Anticoagulants; Dual Anti-Platelet Therapy; Echocardiogra

2020
[Transient left ventricular apical ballooning syndrome--a case report].
    Kardiologia polska, 2007, Volume: 65, Issue:2

    Topics: Aged; Amlodipine; Echocardiography, Doppler; Electrocardiography; Enoxaparin; Female; Humans; Simvas

2007